Drug industry: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
Pat Palmer (talk | contribs) m (Text replacement - "United States" to "United States of America") |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 6: | Line 6: | ||
==Regulation== | ==Regulation== | ||
In the [[United States]], the [[Food and Drug Administration]] provides regulation. | In the [[United States of America]], the [[Food and Drug Administration]] provides regulation: | ||
* The [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm Division of Drug Marketing, Advertising, and Communications] (DDMAC) regulates direct-to-consumer advertising. | |||
* The [http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm Orange Book] summarizes evaluations of therapeutic equivalence for [[generic drug]]s. | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 10:46, 2 February 2023
In health care, the drug industry (or pharmaceutical industry) is "that segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function."[1] The chemical products may be medications.
Marketing
Marketing by drug industry can influence prescribing by health care providers.[2] This may lead to conflict of interest for health care providers if they are compensated during marketing.
Regulation
In the United States of America, the Food and Drug Administration provides regulation:
- The Division of Drug Marketing, Advertising, and Communications (DDMAC) regulates direct-to-consumer advertising.
- The Orange Book summarizes evaluations of therapeutic equivalence for generic drugs.
References
- ↑ Anonymous (2024), Drug industry (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, et al. 2010 Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Med 7(10): e1000352. DOI:10.1371/journal.pmed.1000352